Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific's outlook is bolstered by anticipated procedural growth, with projections indicating a modest 5-10% increase in combined atrial fibrillation (AF) ablation and left atrial appendage closure (LAAC) procedures, alongside a potential 20-30% volume increase driven by positive CHAMPION-AF trial outcomes. The company is expected to capture significant market growth, with the global AFib market anticipated to rise from $9 billion to $15 billion by 2028, alongside its electrophysiology (EP) market growing to approximately $20 billion, reflecting a compound annual growth rate (CAGR) of 15%. Positive survey trends suggest healthcare professionals foresee an average 18% increase in procedure volumes stemming from recent trial results, underscoring strong demand for Boston Scientific's innovative medical devices.

Bears say

Boston Scientific faces a negative outlook due to a projected decline in its core ablation product segments, with radiofrequency ablation sales expected to decrease by 1,110 basis points and cryoablation by 500 basis points by 2030. Additional headwinds include slower-than-expected adoption of its product portfolio, limited operational leverage with operating margin expansion falling short of its goals, and the potential for increased debt levels from mergers and acquisitions adversely affecting its financial leverage. Furthermore, competition in key markets, delays in product approvals, and risks associated with clinical trials could further hamper the company’s future growth prospects.

Boston Scientific (BSX) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 20 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.